ACN Newswire

2024-08-06 11:42

Research Analysis: Fosun is on Track for Valuation Recovery

HONG KONG, Aug 6, 2024 - (ACN Newswire) - “Fosun International (00656.HK) continues to focus on its core industries and optimize operational capabilities, resulting in increased earnings certainty, stable cash flow improvement, and continuous dividend growth. It is expected that Fosun’s valuation set for gradual recovery.” On 5 August, Fosun International Securities released a research report, providing an in-depth analysis of Fosun International’s investment value from four aspects: core subsidiaries’ performance, globalization and industrial operational capabilities, balance sheet recovery, and dividend expectations. The report issues a “Buy” rating on Fosun International with a target price of HKD13 per share.

The research report points out that after more than 30 years of development, Fosun International has successfully implemented its “investment + operation” strategy. Through globalized and diversified mergers and acquisitions and industry operations, Fosun has formed four major business segments: Health, Happiness (Consumption), Wealth (Finance and Insurance), and Intelligent Manufacturing. In 2019, Fosun positioned itself as an “innovation-driven consumer group”. In early 2020, it proposed a focused strategy, shifting its focus to profound industry operations, accelerating the divestment of non-core assets, and improving financial indicators to effectively focus on its core businesses and strengthen its asset-light operation capabilities.

The report further analyzes from a medium-to-long-term perspective, suggesting that four key drivers will support Fosun International’s significant value recovery.

Firstly, the performance and valuation of Fosun’s core subsidiaries are expected to gradually improve. Fosun International owns high-quality global assets in the pharmaceutical, consumption and financial sectors. Its core subsidiaries continue to deepen their industry operations and steadily increase their market share in their respective sectors. In 2023, the four core subsidiaries, Fosun Pharma, Yuyuan, Fosun Tourism Group, and Fosun Insurance Portugal, contributed a total revenue ratio of 72%, ranking among the top players in their respective industries. They maintained stable revenue and profit growth overall and continued to pay dividends. Since the pandemic, some subsidiaries have been affected by the uncertain macroeconomic environment and weak Hong Kong stock market sentiment. At the same time, short-term profits have been dragged down by the divestment of some investment projects during the market downturn, resulting in their stock prices under pressure. However, after the listed subsidiaries optimize their operations, the significant recovery of their valuations helps boost Fosun International’s valuation. Meanwhile, some subsidiaries’ optimization in capital structure will also help improve valuations. For example, in June 2024, Fosun Pharma announced its plan to privatize its subsidiary Shanghai Henlius through an absorption merger.

Secondly, Fosun’s strong globalization and industrial operational capabilities increase earnings stability and profit growth potential. Fosun International has outstanding globalization capabilities, continuously optimized industrial operational capabilities, and the ability to cooperate with parties who possess abundant resources. It has extensive successful experience in industrial mergers and acquisitions, asset divestment, and an effective organizational management mechanism to ensure execution. The comprehensive competitiveness led by globalization and industrial operational capabilities enables Fosun to grasp the direction of macroeconomic policies, make timely strategic and tactical adjustments to ensure overall operational stability, and enhance operations and performance in core industries, thereby increasing profit growth potential and opportunities for exceeding expectations. Fosun International’s overseas business contributes nearly half of its revenue, demonstrating its profound global operational capabilities, expansion and growth potential, as well as its strong capability to hedge against macro and regional risks. For example, Shanghai Henlius, a holding subsidiary of Fosun Pharma, has received US approval for its independently developed biosimilar HANQUYOU, becoming the Chinese monoclonal antibody biosimilar approved in China, the EU, and the US. Moreover, it has been approved for marketing in over 40 countries and regions. After Fosun’s acquisition, Club Med quickly turned losses into profits and became a leading brand of global resorts. Yuyuan’s Laomiao gold jewelry brand has maintained its market share among the top three in China’s gold jewelry industry since 2019, thanks to its strong new product iteration and differentiated marketing capabilities in recent years.

Thirdly, continuous debt reduction and significant balance sheet recovery support valuation improvement. Since 2021, Fosun International has continuously optimized its capital and asset structure, reduced its debt scale, continuously improved its financial indicators, and significantly reduced its leverage ratio. In May 2023, S&P Global revised Fosun’s rating outlook from “negative” to “stable”. In May 2024, S&P reaffirmed Fosun’s “stable” rating, recognizing the improvement in its balance sheet. Currently, the yield on Fosun International’s offshore bonds maturing between 2025 and 2027 is in a good range of 8.5% to 9.5%, but its stock valuation has fallen to a historical low. It is expected that factors such as rating agency upgrades and steady overall revenue growth will gradually be recognized by equity investors, increasing the opportunity for valuation improvement.

Fourthly, the effective implementation of the focused strategy brings opportunities for exceeding expectations in dividend increases. Fosun International’s core assets are concentrated in leading growth and value-oriented companies in their respective industries. It focuses on supporting core enterprises to achieve long-term strategic goals, driving industry development, complementing industries through mergers and acquisitions, and achieving value realization through timely and balanced investment and divestment, thus creating excess capital returns for shareholders. However, the market continues to overlook the room for improvement in Fosun’s revenues and profitability. At the same time, Fosun optimizes the operations of its subsidiaries through internationalization and ecosystem empowerment, continuously building top-tier business segments, maintaining steady growth in core businesses, and increasing dividends in some mature businesses. In addition to providing investors with stable dividends while optimizing performance, based on the previous dividend payout ratio of 20%, Fosun has the ability to further increase the dividend payout ratio, presenting shareholders with the opportunity for dividend returns to exceed expectations in the future.

The research report also points out that Fosun International was still negatively affected by the macro environment in the first half of 2024, and profits in the short-term are expected to be under pressure. However, the focus on industry operations has led to a gradual improvement in operating conditions and optimization of core asset performance. Leading indicators of Fosun’s improving performance are poised to become positive catalysts for the stock price.

The research report forecasts Fosun International’s revenue growth rate in 2024/25/26 to be 9.4%, 9.6%, and 8.6% respectively, and its profit attributable to owner of the parent to grow by 46.6%, 81.9%, and 55.0% respectively. Based on the sum-of-the-parts (SOTP) valuation method, the target price is set at HKD13 per share, corresponding to 0.7x 2024e P/B, issuing a “Buy” rating on Fosun International.



Copyright 2024 ACN Newswire. All rights reserved. www.acnnewswire.com

人氣文章
最近7天
1
專訪|林本利系列專訪逢周五登場,股市篇:勿驚美股調整,港股那些可以放心買那些勿沾手(有片)
2
神州經脈 | 特別國債或發3萬億,滬指逼近三千四,日外相訪華
3
神州經脈 | 工業利潤降幅收窄,低空經濟發展司成立,滬指全周升
4
高息定存 | 信銀國際上調1個月定存年息至高達3.88厘
5
高息定存 | 聖誕前夕銀行加存息吸資金,大眾3個月加至3.6厘
6
今日焦點股 | 據報螞蟻集團重組架構,劉政或出任首席財務官
7
【FOCUS】「晶片戰」揮新大棒,技術制華恐適得其反
8
回顧展望-國際形勢 | 全球動盪戰火連天,特朗普時代重臨
9
回顧展望-國際金融 | 金融市場現重要轉折,戰亂刺激避險
10
港股 | 蕭猷華:恒指春節前可挑戰21500點
1
高息定存 | 一周高息合集,信銀國際3個月有3.88厘
2
高息定存 | 工銀亞洲新推38日4.08厘,集友3個月加至3.7厘
3
高息定存 | 滙豐3個月港元存息高達3.8厘,6個月3.55厘
4
高息定存 | 一周高息合集,大新3個月最高4.1厘,華僑及信銀國際見4厘
5
【FOCUS】豪賭折射威權脆弱,尹錫悅去留牽動地緣
6
高息定存 | 銀行高息搶存,東亞上調3個月定存息至3.9厘,花旗加至3.7厘
7
南韓戒嚴 | 韓國防部長金龍顯辭職
8
高息定存 | 華僑推3個月快閃達4厘,信銀國際全線升3個月存息
9
港股 | 蕭猷華:恒指料反彈,短線看幾多?
10
呂志和喪禮|呂志和香港殯儀館設靈,中聯辦鄭雁雄、李家超、陳啟宗等人到場(圖集)
11
局長換人 | 國務院:免去林世雄、楊潤雄局長職務,任命陳美寶、羅淑佩接任(楊潤雄facebook回應)
12
熊貓經濟 | 2500隻大熊貓雕塑抵港,周六起星光大道等地展出
13
一周部署 | 非農數據前美股料穩,OPEC+會議全球矚目
14
傾力救市 | 華爾街大行預計中國明年降息幅度將達十年來最大
15
建銀國際料明年恒指先低後高,波動區間18000至23000點
16
高息定存 | 建行亞洲上調3個月存息至3.85厘,富邦3.8厘
17
港股 | 蕭猷華:關注中央經濟工作會議,美團股價落後
18
高息定存 | 華僑銀行208日定存年息高達3.8厘
19
基建債券 | 認購額178.5億首未足額,發言人:受減息步伐影響
20
神州經脈 | 政治局會議定調明年貨幣政策適度寬鬆,CPI遜預期
21
新股 |【FOCUS】毛戈平膺「凍資王」,驚艷之後魅力臨考
22
詹培忠父子涉隱瞞秘密「買殼」串謀欺詐罪成
23
神州經脈 | 11月進出口數據降溫,貨幣政策轉向股匯齊漲
24
神州經脈 | 回購增持貸細則調整,13美國軍工企業遭反制
25
專訪|林本利系列專訪逢周五登場,股市篇:勿驚美股調整,港股那些可以放心買那些勿沾手(有片)
26
專訪|林本利系列專訪一連三個周五登場,樓市篇:中原指數長線重返180,買樓勿買新樓(有片)
27
特首述職|習近平讚揚李家超務實進取,中央全力支持帶領各界改革
28
滙控 | 擬推改革削減成本,股價再創17年新高,聖誕鐘真係要買滙豐?
29
神州經脈 | 特別國債或發3萬億,滬指逼近三千四,日外相訪華
30
資源有限窒礙中小企轉型? 營商生態圈助你開拓無限商機!
專業版
HV2
精裝版
SV2
串流版
IQ 登入
強化版
TQ
強化版
MQ

【etnet 30周年】多重慶祝活動一浪接一浪,好禮連環賞!

【etnet30周年連環賞】睇住賞Moon-River RELOVE 蛋白酵素去漬抑菌手洗精 (價值HK$188)

etnet榮獲HKEX Awards 2023 「最佳證券數據供應商」大獎

回顧24 展望25

貨幣攻略

大國博弈

說說心理話

聖誕新年特輯

Watche Trends 2024

北上食買玩

Artcation

秋冬養生食療

消委會報告

山今養生智慧

輕鬆護老